Third Harmonic Bio, Inc. (THRD) Stock Analysis & Investment Frameworks
Third Harmonic Bio, Inc. (THRD) stock analysis on Invetso. Review Third Harmonic Bio, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Third Harmonic Bio, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Third Harmonic Bio, Inc. Key Financial Metrics
- Market Cap: $242.79M
- Revenue: $N/A
- P/E Ratio: 5.33
- ROE: 16.41%
- ROIC: 20.42%
- Dividend Yield: N/A
About Third Harmonic Bio, Inc.
Third Harmonic Bio, Inc. is a clinical-stage biotechnology firm dedicated to creating therapeutic solutions for a range of allergic and inflammatory conditions. Their primary investigational compound is THB001, an orally administered small-molecule inhibitor targeting KIT. This compound is being advanced to address chronic urticaria—a skin ailment characterized by painful, itchy red welts (hives) stemming from mast cell overactivity—and is also being explored for its potential in respiratory and digestive tract disorders. Previously known as Project IGE, Inc., the company adopted its current name, Third Harmonic Bio, Inc., in June of 2019. Established in 2019, its corporate headquarters are situated in Cambridge, Massachusetts.